[go: up one dir, main page]

MX2010003261A - Analogos de azacitidina y usos de los mismos. - Google Patents

Analogos de azacitidina y usos de los mismos.

Info

Publication number
MX2010003261A
MX2010003261A MX2010003261A MX2010003261A MX2010003261A MX 2010003261 A MX2010003261 A MX 2010003261A MX 2010003261 A MX2010003261 A MX 2010003261A MX 2010003261 A MX2010003261 A MX 2010003261A MX 2010003261 A MX2010003261 A MX 2010003261A
Authority
MX
Mexico
Prior art keywords
integer
formula
r5ch2oc
r5ch2nhc
compounds
Prior art date
Application number
MX2010003261A
Other languages
English (en)
Inventor
Lewis Silverman
James Holland
Finn Myhren
Ole Henrik Eriksen
Marit Liland
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Publication of MX2010003261A publication Critical patent/MX2010003261A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención está dirigida a compuestos de la Fórmula (I) como sigue, en donde R es H, R5C(O), R5CH2OC(O), o R5CH2NHC(O); R1 es: en donde a línea punteada cruzada ilustre el enlace formado que une R1 a la molécula de la Fórmula (I); R2 y R3 son independientemente OH o H, siempre que R2 y R3 no sean simultáneamente OH; R4 es H, R5C(O), R5CH2OC(O) o R5CH2NHC(O), siempre que R y R4 no sean simultáneamente H; y R5 tiene la fórmula general: CH3-(CH2)n(CH=CH-CH2)m-CH=CH-(CH2)k-; k es un entero de 0 a 7; m es un entero de 0 a 2; y n es un entero de 0 a 10, o una sal farmacéutica del mismo. Se describen también métodos para elaborar y usar estos compuestos.
MX2010003261A 2007-09-26 2008-09-25 Analogos de azacitidina y usos de los mismos. MX2010003261A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97543707P 2007-09-26 2007-09-26
PCT/US2008/077673 WO2009042767A1 (en) 2007-09-26 2008-09-25 Azacytidine analogues and uses thereof

Publications (1)

Publication Number Publication Date
MX2010003261A true MX2010003261A (es) 2010-08-18

Family

ID=40511851

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010003261A MX2010003261A (es) 2007-09-26 2008-09-25 Analogos de azacitidina y usos de los mismos.
MX2010003002A MX2010003002A (es) 2007-09-26 2008-09-25 Analogos de azacitidina y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010003002A MX2010003002A (es) 2007-09-26 2008-09-25 Analogos de azacitidina y sus usos.

Country Status (15)

Country Link
US (2) US8399420B2 (es)
EP (2) EP2205073A4 (es)
JP (2) JP2010540556A (es)
KR (2) KR20100102092A (es)
CN (2) CN101815437A (es)
AU (2) AU2008304380A1 (es)
BR (2) BRPI0817234A2 (es)
CA (2) CA2700267A1 (es)
IL (1) IL204690A0 (es)
MX (2) MX2010003261A (es)
NZ (2) NZ583923A (es)
RU (1) RU2488591C2 (es)
UA (2) UA99308C2 (es)
WO (2) WO2009042767A1 (es)
ZA (1) ZA201001660B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
CN101815437A (zh) * 2007-09-26 2010-08-25 辛乃山医学院 氮杂胞苷类似物和其应用
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2424845A4 (en) * 2009-04-27 2014-03-05 Reddys Lab Ltd Dr PREPARATION OF DECITABIN
EP2670396A1 (en) 2011-01-31 2013-12-11 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
US20120264710A1 (en) * 2011-04-15 2012-10-18 Marit Liland Sandvold Systems and Methods for Detecting hENT1 Expression in Hematological Disorders
PH12014500965A1 (en) 2011-11-01 2014-06-30 Celgene Corp Methods for treating cancers using oral formulations of cytidine analogs
MY174308A (en) 2012-02-24 2020-04-06 Signal Pharm Llc Methods for treating non-small cell lung using tor kinase inhibitor combination therapy
US9493500B2 (en) 2012-07-19 2016-11-15 Richard Daifuku Fluorinated pyrimidine analogs and methods of use thereof
CN105392499B (zh) * 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
WO2015195786A2 (en) 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
ES2892123T3 (es) * 2014-12-26 2022-02-02 Univ Emory Derivados antivíricos de N4-hidroxicitidina
WO2017090264A1 (ja) 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
JP7194021B2 (ja) 2015-12-03 2022-12-21 エピデスティニー，インコーポレイテッド デシタビン、５アザシチジンおよびテトラヒドロウリジンを含有する組成物およびその使用
PL3600419T3 (pl) 2017-03-20 2024-02-19 Vaccinex, Inc. Leczenie raka przeciwciałem wiążącym semaforynę-4d w kombinacji ze środkiem epigenetycznie modulującym
JP7282045B2 (ja) 2017-06-22 2023-05-26 セルジーン コーポレイション Ｂ型肝炎ウイルス感染を特徴とする肝細胞癌の治療
CA3097003A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
WO2022035852A1 (en) * 2020-08-10 2022-02-17 The Johns Hopkins University Decitabine analogs for immunological and oncological therapy

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612384A (fr) 1961-01-10 1962-05-02 Spofa Vereinigte Pharma Werke Procédé de préparation des 1-glycosyle-6-aza-uraciles
GB1050899A (es) 1963-12-22
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
US3984396A (en) 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3998807A (en) 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
US4172889A (en) * 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
US4405611A (en) 1980-06-27 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services Bisulfite stabilization of 5-azacytidine
DE3100478A1 (de) 1981-01-09 1982-08-12 Dr. Thilo & Co GmbH, 8021 Sauerlach 5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
DE3737456A1 (de) 1986-11-04 1988-05-19 Fuji Photo Film Co Ltd Laserlichtquelle
CS264454B1 (cs) 1987-08-28 1989-08-14 Piskala Alois 2'-Deoxy-5,6-dihydro-5-azacytidin a způsob jeho výroby
CS264456B1 (cs) 1987-08-28 1989-08-14 Piskala Alois Způsob výroby 5,6-dihydro-S-azacytidinu
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4984396A (en) * 1988-08-29 1991-01-15 Uragami Fukashi Cleaning device
DE3834435A1 (de) * 1988-10-10 1990-06-13 Basf Ag Verbrueckte, wasserloesliche copolymerisate, verfahren zu ihrer herstellung und ihre verwendung
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
WO1992015113A1 (en) * 1991-02-19 1992-09-03 Fujitsu Limited Semiconductor device having an isolation region enriched in oxygen and a fabrication process thereof
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
HUT70144A (en) 1991-08-14 1995-09-28 Procter & Gamble Pharma Cyclic urethaanes useful as antiarrhythmic and antifibrillatory agents, pharmaceutical compositions containing them, and process for their preparation
GB2260319B (en) 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
GB9515279D0 (en) 1995-07-25 1995-09-20 Norsk Hydro As Improved therapeutic agents
DE19505168A1 (de) 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
WO1997005143A1 (en) 1995-07-25 1997-02-13 Asahi Kasei Kogyo Kabushiki Kaisha Novel group 4 transition metal compounds
BR9610070A (pt) 1995-08-08 1999-07-27 Univ Jefferson Sequência de ácido nucleico polipetídeos compostos antifibrótico e processo para tratar distúrbios ou doenças relacionadas com fibrose para usar a sequência de dna e para produzir c-proteinase recombinante
CA2229414A1 (en) 1995-09-15 1997-03-20 Anadys Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
WO1997044026A1 (en) 1996-05-22 1997-11-27 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
GB2321455A (en) 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
KR100483256B1 (ko) 1997-01-24 2005-04-15 콘파마 아에스 젬시타빈 유도체
US6498149B1 (en) * 1997-06-03 2002-12-24 Tsuneatsu Mori Natural antitumor or antiviral substances and use of the same
WO1999026958A1 (en) 1997-11-25 1999-06-03 Protarga, Inc. Nucleoside analog compositions and uses thereof
US6358960B1 (en) 1998-02-17 2002-03-19 Ono Pharmaceutical Co., Ltd. Amidino derivatives and drugs containing the same as the active ingredient
AU5073100A (en) 1999-06-09 2001-01-02 Bayer Aktiengesellschaft Pyridine carboxamides and their use as plant protection agents
US6752981B1 (en) 1999-09-08 2004-06-22 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
DK1224174T3 (da) 1999-10-15 2004-01-26 Hoffmann La Roche Benzodiazepinderivater
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
NZ533094A (en) 2001-11-21 2006-01-27 Heidelberg Pharma Gmbh Phospholipid derivatives of nucleosides as antitumoral medicaments
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
CA2499036A1 (en) * 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
JPWO2004101593A1 (ja) 2003-05-16 2006-07-13 キッセイ薬品工業株式会社 ５’−修飾ヌクレオシド誘導体及びその医薬用途
US7244732B2 (en) * 2003-06-20 2007-07-17 Koronis Pharmaceuticals, Incorporated Prodrugs of heteroaryl compounds
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
AU2004311702A1 (en) 2003-12-19 2005-07-21 Koronis Pharmaceuticals, Inc. Mutagenic heterocycles
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
BRPI0506881A (pt) 2004-02-04 2007-06-26 Neurosearch As derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou distúrbio ou condição de um corpo de animal vivo
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007035783A2 (en) 2005-09-19 2007-03-29 Celator Pharmaceuticals, Inc. Combination formulations of cytidine analogs and platinum agents
US8993763B2 (en) 2005-09-27 2015-03-31 Shionogi & Co., Ltd. Sulfonamide derivative having PGD2 receptor antagonistic activity
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
US20070225248A1 (en) 2006-03-21 2007-09-27 Clavis Pharma As Oral dosage forms of gemcitabine derivatives
CN101815437A (zh) * 2007-09-26 2010-08-25 辛乃山医学院 氮杂胞苷类似物和其应用

Also Published As

Publication number Publication date
EP2197274A1 (en) 2010-06-23
NZ583824A (en) 2012-06-29
JP2010540555A (ja) 2010-12-24
ZA201001660B (en) 2011-05-25
EP2205073A4 (en) 2013-03-06
RU2488591C2 (ru) 2013-07-27
JP2010540556A (ja) 2010-12-24
EP2205073A1 (en) 2010-07-14
IL204690A0 (en) 2010-11-30
CN101877964A (zh) 2010-11-03
EP2197274A4 (en) 2013-03-06
RU2010116274A (ru) 2011-11-10
KR20100102092A (ko) 2010-09-20
CA2700267A1 (en) 2009-04-02
WO2009042767A1 (en) 2009-04-02
US20090209477A1 (en) 2009-08-20
MX2010003002A (es) 2010-07-05
RU2010116154A (ru) 2011-11-10
US8158605B2 (en) 2012-04-17
US20090209482A1 (en) 2009-08-20
WO2009042766A9 (en) 2009-05-28
CN101815437A (zh) 2010-08-25
BRPI0817269A2 (pt) 2014-10-07
WO2009042766A1 (en) 2009-04-02
AU2008304381A1 (en) 2009-04-02
KR20100072230A (ko) 2010-06-30
AU2008304380A1 (en) 2009-04-02
US8399420B2 (en) 2013-03-19
NZ583923A (en) 2012-05-25
CA2700207A1 (en) 2009-04-02
UA99836C2 (en) 2012-10-10
BRPI0817234A2 (pt) 2014-09-30
UA99308C2 (ru) 2012-08-10

Similar Documents

Publication Publication Date Title
MX2010003261A (es) Analogos de azacitidina y usos de los mismos.
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
NO20091706L (no) Inhibitorer av hepatitt C virus
MX2008002152A (es) Formulacion de bis(tio-hidrazida amida.
EA200970569A1 (ru) Применимые в качестве гербицидных соединений пиридопиразиновые производные
EA201070607A1 (ru) Гербицидные соединения
TW200728307A (en) Novel spirochromanone derivatives
EA200870282A1 (ru) Производные амина
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
NO20091707L (no) Inhibitorer av hepatitt C virus
WO2010005958A3 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
MY151986A (en) Adamantyl diamide derivatives and uses of same
EP3925614A3 (en) Melanocortin receptor ligands
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
EA201270275A1 (ru) Кристаллическое соединение пиридазина
WO2006113509A3 (en) Quinobenzoxazine analogs and methods of using thereof
TW200744659A (en) Preparation for preventing and ameliorating wrinkle
ATE440833T1 (de) Antithrombotische diamide
PT1951747E (pt) Processo e intermediários para a síntese de caspofungina
TW200726469A (en) Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists
TW200734343A (en) Indol-3-yl-carbonyl-spiro-piperidine derivatives
EA200701810A1 (ru) Производное изоксазолина и новый способ его получения
EA200702062A1 (ru) Пиримидиндионовые производные как антагонисты прокинетициновых рецепторов

Legal Events

Date Code Title Description
FA Abandonment or withdrawal